Prevention of drug-induced liver injury in patients with pulmonary tuberculosis and chronic hepatitis C Source: International Congress 2019 – Clinical problems from non-malignant pleural disease to hypoventilation Year: 2019
Risk of adverse effects of antitubercular drugs in patients with pulmonary tuberculosis and low active viral hepatitis C and other digestive tract diseases Source: Annual Congress 2008 - Tuberculosis in immigrants, disadvantaged populations, elderly, HIV-seropositives and in other risk groups Year: 2008
Clinical-evolutive aspects of pulmonary tuberculosis at patients with chronic hepatitis Source: Annual Congress 2007 - Tuberculosis Year: 2007
Influence of viral hepatitis and anti-TB drugs on hepatocyte disfunction in patients with MDR/XDR tuberculosis Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis Year: 2021
The clinical flow and efficiency of treatment of pulmonary tuberculosis in patients with chorine organic pasticides and viral hepatitis ‘B‘ markers Source: Eur Respir J 2004; 24: Suppl. 48, 50s Year: 2004
Results of treatment of patients with pulmonary tuberculosis combined with HIV infection and hepatitis Source: International Congress 2018 – Tuberculosis comorbidities Year: 2018
Influence Liv-52 on activity of the liver monooxygenase systems at patients with pulmonary tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 34s Year: 2004
Relation of D-dimer levels and extent of disease in patients with active tuberculosis infection Source: Eur Respir J 2006; 28: Suppl. 50, 164s Year: 2006
Evaluation of D-dimer levels in patients with active pulmonary tuberculosis and latent tuberculosis infection Source: Eur Respir J 2006; 28: Suppl. 50, 164s Year: 2006
Clinical and morphological outcomes of pulmonary tuberculosis concurrent with chronic hepatitis Source: Eur Respir J 2006; 28: Suppl. 50, 13s Year: 2006
Risk factors of drug -induced hepatitis among patients with TB/HIV co-infection Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities Year: 2010
The impact of bedaquiline and delamanid containing regimens on liver function in patients multi-infected with pulmonary DR-TB, HIV and viral hepatitis Source: International Congress 2019 – Tuberculosis: treatment and management Year: 2019
The risk of hepatotoxicity of anti-tuberculosis drugs in patients from regions with high prevalence of hepatitis B Source: Eur Respir J 2001; 18: Suppl. 33, 312s Year: 2001
The prevalence rate of chronic hepatitis B and C among pulmonary TB patients Source: Annual Congress 2008 - Tuberculosis in immigrants, disadvantaged populations, elderly, HIV-seropositives and in other risk groups Year: 2008
Diagnosis of latent tuberculosis infection in patients with chronic liver disease undergoing liver transplantation: performance of the new IFN-γ-based assays Source: Eur Respir J 2007; 30: Suppl. 51, 752s Year: 2007
Interstitial lung involvement in patients with chronic HCV hepatitis Source: Eur Respir J 2006; 28: Suppl. 50, 744s Year: 2006
Hepatopulmonary syndrome in non-cirrhotic patients with chronic viral hepatitis Source: International Congress 2015 – Pulmonary hypertension in lung disease Year: 2015
Vitamin C levels in Indian patients with active pulmonary tuberculosis Source: Annual Congress 2010 - Tuberculosis: metabolic insights Year: 2010
The role of hepatitis C virus infections in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 333s Year: 2005
Factors associated with sputum culture conversion in patients with pulmonary tuberculosis Source: International Congress 2017 – TB: co-morbidities and outcome Year: 2017